LifeMD Sets Q4 Revenue Guidance at $46M-$49M
The telehealth company lowered its full-year 2026 outlook after third-quarter sales came in below prior guidance.
Updated on Nov. 13, 2026 in Healthcare

LifeMD set fourth-quarter 2026 revenue guidance at $46 million to $49 million after reporting third-quarter sales of $44.6 million, which fell below its previously guided range. The company also lowered its full-year 2026 revenue outlook to $188 million to $191 million.
Why it matters
The guidance cut reflects weaker-than-expected sales and signals that LifeMD is cutting costs to address its losses. The company's push to reduce operating expenses by 30% by Q1 2027 points to a shift toward tighter spending as it works through its current financial position.
LifeMD reported $44.6 million in third-quarter 2026 sales and ended the quarter with $21.9 million in cash and no debt. Its full-year 2026 adjusted EBITDA loss is forecast at $10.6 million to $12.6 million, with the fourth-quarter loss projected at $2 million to $4 million.
The players
LifeMD, Inc.
A telehealth company that offers virtual care and prescription services to patients across the United States.
Eli Lilly
A major pharmaceutical company whose products Zepbound and Foundayo are part of LifeMD's arrangements.
Novo Nordisk
A Danish pharmaceutical company with which LifeMD has existing arrangements.
The details
LifeMD said third-quarter sales came in below the range it had previously guided, prompting the lower full-year outlook. The company excluded enterprise efforts and new pharmacy products from its near-term guidance, and announced on Nov. 5 a mail-order option for Eli Lilly's Zepbound and Foundayo.
Timeline
Nov. 5, 2026: LifeMD announced a mail-order option for Zepbound and Foundayo.
Q1 2027: Target date for reducing operating expenses by 30%.
Market Landscape
LifeMD's sales shortfall and guidance reduction come as telehealth providers compete for GLP-1 prescriptions alongside drugmakers' own direct-to-patient channels. The company's push to cut operating costs by 30% reflects pressure to protect margins in a crowded market.
Patients using LifeMD for telehealth prescriptions could see changes in product availability as the company restructures around new pharmacy offerings. The mail-order option for Zepbound and Foundayo gives patients another way to obtain these medications.
The takeaway
A company's revised revenue guidance and expense targets can signal shifting financial pressure before results fully reflect it. Readers tracking healthcare companies should watch whether cost reductions and projected 2027 growth materialize as stated.
What happens next
LifeMD targets a 30% reduction in operating expenses by Q1 2027, the next checkpoint for its cost-cutting plan.
Further reading
For more on the sector, explore Healthcare coverage on Wisevoter.









